| 研究課題/領域番号 |
25860853
|
|---|
| 研究種目 |
若手研究(B)
|
| 研究機関 | 信州大学 |
|---|
研究代表者 |
岳 鳳鳴 信州大学, 医学部, 助教 (20532865)
|
|---|
| 研究期間 (年度) |
2013-04-01 – 2016-03-31
|
| キーワード | patient- iPS cells / VSMCs / cardiomyocyte / disease model |
|---|
| 研究概要 |
D4ST1-deficient Ehlers-Danlos syndrome (DD-EDS, Kosho type) is a rare heterogeneous connective tissue disorder. Patients suffer from serious subcutaneous hematoma which is possible caused by insufficient contraction of the arterial smooth muscle. In this project, we investigate mechanism of hematoma using with using patient-specific iPS cell-derived vessel smooth muscle cells (VSMCs).
In research plan for 2013, I made a plan to induce vessel smooth muscle cells from patient-specific iPS cells. According to this plan, we induced the differentiation of DD-EDS-specific iPS cells and normal iPS cells into origin-specific VSMCs, and identified iPS cell-derived VSMCs by immunocytochemistry method.
In addition, in order to make circulation-system model, I also successfully induced the differentiation of patient-specific iPS-derived cardiomyocyte.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
According to the application form innitially planned, I should induced the differentiation of vessel smooth muscle cells and compared compared differentiation efficiency in patient-iPS and normal iPS cells.
During 2013, I finally induced the VSMCs from not only normal iPS cells but also patient specific-iPS cells successfully, although I failed it for several times using with two kinds of methods which had beem published by other reseacheres.
In addition, in order to made disease model for circulation system research, I induced the differentiation of cardiomyocyte from patient-specific iPS cells.
Therefore, so far, I thoughtthat the whole project is processing smoothly, although I run across some difficulty when inducing the differentiation of smooth muscle cells and cardiomyocyte from iPS cells at the beginning stage.
|
| 今後の研究の推進方策 |
Since I have induced the differentiaiton of VSMCs from patient-specific iPS cells successfully, in the following 2014 year, I plan to compare the difference of iPS-derived VSMCs from patient-iPS and normal iPS cells, including the differentiation deficiency and function of smooth muscle cells, especially, contractile protein, contractile in response to pharmacological agonists such as carbachol or KCl, and vessel formation in matrigel plugs.
|
